Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | TERT | O14746 | 3/20 | 0.44 |
| ▸ | TOP1 | P11387 | 3/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 3/20 | 0.43 |
| ▸ | CYCS | P99999 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584947 | 1.00 | NR5A1 (0.57) | NR5A1LTA4HTERTTOP1GPR84 | |
| SCHEMBL584866 | 1.00 | NR5A1 (0.57) | NR5A1LTA4HTERTTOP1GPR84 | |
| SCHEMBL585830 | 1.00 | NR5A1 (0.57) | NR5A1LTA4HTERTTOP1GPR84 | |
| SCHEMBL585439 | 1.00 | NR5A1 (0.57) | NR5A1LTA4HTERTTOP1GPR84 | |
| SCHEMBL585897 | 1.00 | NR5A1 (0.57) | NR5A1LTA4HTERTTOP1GPR84 | |
| SCHEMBL586280 | 1.00 | NR5A1 (0.57) | NR5A1LTA4HTERTTOP1GPR84 | |
| SCHEMBL584872 | 1.00 | NR5A1 (0.57) | NR5A1LTA4HTERTTOP1GPR84 | |
| SCHEMBL584873 | 1.00 | NR5A1 (0.57) | NR5A1LTA4HTERTTOP1GPR84 | |
| SCHEMBL584741 | 1.00 | NR5A1 (0.57) | NR5A1LTA4HTERTTOP1GPR84 | |
| SCHEMBL8031578 | 0.94 | TERT (0.49) | NR5A1TERTTOP1RARBCYCS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | disclosed |
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| EP-1897883-A2 | Cationic porphyrin derivatives as antibacterial agents | Destiny Pharma Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | DESTINY PHARMA LIMITED | 2007-12-06 | — | — | US | disclosed |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | DESTINY PHARMA LIMITED | 2007-12-06 | — | — | US | disclosed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20070167619-A1 | Novel uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| US-20070167619-A1 | Novel uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| EP-1768666-A1 | NOVEL USES OF PORPHYRIN COMPOUNDS | Destiny Pharma Limited (GB) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006000765-A1 | NOVEL USES | DESTINY PHARMA LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| US-20040143001-A1 | Novel compounds and uses thereof | DESTINY PHARMA LIMITED | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167619-A1 | Novel uses of porphyrin compounds | PPOX, ZFX, ZYX | NR5A1 2010/4885LTA4H 3552/4885TERT 732/4885 |
| US-20040143001-A1 | Novel compounds and uses thereof | PPOX, CYP19A1, XDH | NR5A1 271/4885LTA4H 795/4885TERT 2368/4885 |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | PPOX, PPIF, TYR | NR5A1 1247/4885LTA4H 1756/4885TERT 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.